Sector
PharmaceuticalsCMP
as on 03 Jul, 2024 12:00:00 AM
Open
₹1,494Prev. Close
₹1,488.65Turnover(Lac.)
₹15,746.25Day's High
₹1,500Day's Low
₹1,474.652 Week's High
₹1,58252 Week's Low
₹996.5Book Value
₹355.6Face Value
₹2Mkt Cap (₹ Cr.)
1,19,815.48P/E
32.24EPS
46Divi. Yield
0.5711 Jul 2023
12:00 AM
AGM
Announcement Date: 11 Jul, 2023
11 May 2023
12:00 AM
Dividend
Dividend Amount: 8.5
Record Date: 21 Jul, 2023
5 Apr 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 161.43 | 161.36 | 161.29 | 161.25 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 24,476.66 | 22,352.19 | 19,766.27 | 17,241.71 |
Net Worth | 24,638.09 | 22,513.55 | 19,927.56 | 17,402.96 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 13,091.79 | 11,302.71 | 12,659.15 | 11,389.9 |
yoy growth (%) | 15.82 | -10.71 | 11.14 | 5.77 |
Raw materials | -5,090.24 | -4,103.61 | -4,319.21 | -4,155.49 |
As % of sales | 38.88 | 36.3 | 34.11 | 36.48 |
Employee costs | -1,729.16 | -1,703.58 | -1,911.08 | -1,785.94 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 3,546.23 | 2,784 | 2,964.31 | 1,988.92 |
Depreciation | -460.01 | -468.62 | -599.78 | -529.61 |
Tax paid | -856.84 | -739.35 | -646.14 | -442.88 |
Working capital | 1,126.76 | -61.34 | 1,238.17 | 865.57 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.82 | -10.71 | 11.14 | 5.77 |
Op profit growth | 9.74 | 13.3 | 23.3 | 37.54 |
EBIT growth | 26.3 | -5.7 | 49.95 | 63.18 |
Net profit growth | 19.83 | 6.47 | 57.85 | 50.62 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 25,446.63 | 22,473.18 | 21,623.36 | 18,988.52 | 16,694.85 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 25,446.63 | 22,473.18 | 21,623.36 | 18,988.52 | 16,694.85 |
Other Operating Income | 327.46 | 279.94 | 139.98 | 171.07 | 437.14 |
Other Income | 746.57 | 475.45 | 280.91 | 265.99 | 344.2 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,528.2 | 120.29 | 3,65,682.64 | 867.6 | 0.89 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,575.2 | 76.97 | 1,21,312.5 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,484.45 | 32.36 | 1,20,195.02 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,110.4 | 31.35 | 1,08,114.81 | 1,405.2 | 0.28 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,452 | 24.48 | 1,06,298.05 | 1,034.8 | 0.63 | 5,081.8 | 1,453.02 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Y K Hamied
Vice Chairman
M K Hamied
Non-Exec & Non-Independent Dir
S Radhakrishnan
Non-Exec. & Independent Dir.
Ashok Sinha
Non-Exec. & Independent Dir.
Peter Mugyenyi
Non-Exec. & Independent Dir.
Adil Zainulbhai
Non-Exec. & Independent Dir.
Punita Lal
Executive Vice Chairperson
Samina Hamied
Managing Director & Global CEO
Umang Vohra
Company Sec. & Compli. Officer
Rajendra Chopra
Independent Director
Robert A Stewart
Independent Director
P R Ramesh
Independent Director
Mandar Purushottam Vaidya
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Cipla Ltd
Summary
Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). Ciplas product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets. Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Ltd was incorporated in the year 1935 with the name Chemical, Industrial & Pharmaceutical Laboratories Ltd. Khwaja Abdul Hamied, the founder of Cipla gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorized capital of Rs 6 lakh. From its first manufacturing unit at Bombay Central in 1936, Cipla now has over 40 state-of-the art manufacturing facilities across the globe including India, USA, China and South Africa.In the year 1941, as the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort. In the year 1952, the company se
Read More
What is the Cipla Ltd share price today?
The Cipla Ltd shares price on nse is Rs.₹1483.75 today.
What is the Market Cap of Cipla Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Cipla Ltd is ₹119815.48 Cr. as of 03 Jul ‘24
What is the PE and PB ratio of Cipla Ltd?
The PE and PB ratios of Cipla Ltd is 32.24 and 4.28 as of 03 Jul ‘24
What is the 52 Week High and Low of Cipla Ltd?
The 52-week high/low is the highest and lowest price at which a Cipla Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Cipla Ltd is ₹996.5 and ₹1582 as of 03 Jul ‘24
What is the CAGR of Cipla Ltd?
Cipla Ltd's CAGR for 5 Years at 21.80%, 3 Years at 14.98%, 1 Year at 48.60%, 6 Month at 16.16%, 3 Month at -0.05% and 1 Month at 2.50%.
What is the shareholding pattern of Cipla Ltd?
The shareholding pattern of Cipla Ltd is as follows:
Promoters - 33.40 %
Institutions - 50.15 %
Public - 16.25 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
